We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


MAPS and Wesana Health Resume Final Negotiations

MAPS and Wesana Health Resume Final Negotiations content piece image
Credit: Gerd Altmann/ Pixabay
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

Wesana Health Holdings Inc.  (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), a data-driven life sciences company, is pleased to announce receipt of  a commercial viability analysis conducted by the Boston Consulting Group (BCG) which validated and will expedite Wesana’s partnership talks with Multidisciplinary Association for Psychedelic Studies (MAPS) and MAPS Public Benefit Corporation (MAPS PBC) to move forward in the parties’ definitive agreement to study the use of MDMA-assisted therapy to treat symptoms associated with traumatic brain injury (TBI).

“This analysis brings us one step closer to partnering with Wesana to conduct research into the potential of MDMA-assisted therapy in the massively underserved TBI population,” said MAPS Executive Director, Rick Doblin, Ph.D. “This market analysis makes the case even more compelling for our partnership.”

Daniel Carcillo, CEO of Wesana Health added, “The receipt of favorable results in the MAPS-commissioned BCG report is a critical milestone in what will be the first-of-its-kind collaboration between MAPS and Wesana, facilitating our definitive agreement conversations regarding MDMA-assisted therapy for TBI symptoms.”

The BCG report forecasts a continuing favorable environment for this collaboration. The agreement is expected to accelerate the parties’ research timelines and as well as provide additional support for further investigation, advocacy, education, and equitable access to MDMA-assisted therapy for TBI symptoms.

Carcillo continued, “With the overall reported cost of TBI in the range of ~$76.5 billion annually in the US, we know the market is ready for a new solution. We remain committed to this important work and as we move toward our goal of MDMA-assisted therapy for TBI, we are thrilled to move forward with our efforts deliver meaningful help to victims, families, friends and communities whose lives have been impacted by TBI.”